Company intelligence / Profile preview
Suzhou Alphamab Co., Ltd.
Suzhou, Jiangsu, Chinaalphamab.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Suzhou Alphamab is a clinical-stage, innovation-driven biotech company specializing in biologics R&D, with a pipeline spanning hematology, oncology, endocrinology, and anti-infectives, including multiple programs in late-stage clinical trials in China[1][6]. The company has not yet reported commercialized products but has advanced candidates in pivotal studies.
- Therapeutic areas
- EndocrinologyInfectious DiseasesHematologyCardiovascularOncology
- Modalities
- Monoclonal antibodyFusion proteinNanobodyAntibody-drug conjugateBiosimilarRecombinant protein
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Shanghai Institute of Materia Medica, Chinese Academy of SciencesSoutheast UniversityThermo Scientific
Beyond the preview
Go deeper on Suzhou Alphamab Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Alphamab Co., Ltd..